


# Novartis organizational structure



<sup>1</sup>John Tsai will step down from the Executive Committee on May 15, 2022. Effective May 16, 2022, Shreeram Aradhye will assume the role of President, Global Drug Development & Chief Medical Officer..

<sup>2</sup>Lutz Hegemann will remain a permanent attendee of the Executive Committee.

<sup>3</sup>Victor Bulto was appointed President, Innovative Medicines US on April 4, 2022. Effective May 1, 2022, he will become a member of the Executive Committee.

<sup>4</sup>Effective May 1, 2022, Natacha Theytaz will step down from her current position to take on a new role at Novartis. Kees Roks will assume the role of Chief Audit Officer.